Major neurocognitive disorder, the DSM-5-TR term for what clinicians still call dementia, is an acquired decline from a prior level of cognitive function severe enough to interfere with independence in everyday activities. It is among the most common reasons older adults present to psychiatry, neurology, and primary care, and its prevalence is rising sharply as populations age. The diagnostic framework in DSM-5-TR is etiology-agnostic at the syndromic level — the clinician first establishes the syndrome, then assigns a probable etiologic subtype (Alzheimer disease, vascular, Lewy body, frontotemporal, traumatic brain injury, Parkinson disease, HIV, prion, substance-induced, another medical condition, multiple etiologies, or unspecified). Recognizing the syndrome, characterizing its trajectory, distinguishing it from delirium and depression, and addressing the behavioral and psychological symptoms that drive caregiver burden are the core clinical tasks. Disease-modifying therapy remains limited and the central work of management is functional preservation, behavioral symptom control, and family support.

Major neurocognitive disorder is overwhelmingly a disease of late life, and its frequency rises steeply with each decade after 65. Global burden estimates exceed 55 million people living with dementia worldwide, with roughly 10 million new cases annually.^[1]

Prevalence and incidence

• Prevalence approximately doubles every 5 years after age 65, reaching 25-50% in those over 85.^[1-2]
• Alzheimer disease accounts for 60-80% of cases, with mixed Alzheimer-vascular pathology common at autopsy.^[2]
• Vascular neurocognitive disorder is the second most common etiology in most cohorts.^[2]
• Dementia with Lewy bodies and frontotemporal dementia together account for roughly 10-15% of cases in clinical series.^[2]

Demographics

• Women have a higher lifetime risk of Alzheimer disease, partly attributable to longer life expectancy.^[2]
• Frontotemporal dementia is the most common cause of dementia under age 65 alongside early-onset Alzheimer disease.^[3]

Risk factors

• Non-modifiable: age, family history, APOE ε4 allele for Alzheimer disease, female sex for Alzheimer disease.^[2,4]
• Modifiable risks identified by the 2024 Lancet Commission update account for approximately 45% of population-attributable risk across 14 factors: less education, hearing loss, untreated vision loss, hypertension, high LDL cholesterol, smoking, obesity, depression, physical inactivity, diabetes, excessive alcohol, traumatic brain injury, air pollution, and social isolation.^[4]
• Cerebrovascular risk factors (hypertension, diabetes, atrial fibrillation, hyperlipidemia) contribute to both vascular and Alzheimer pathologies.^[4]

Comorbidity

• Depression frequently co-occurs and may precede, accompany, or follow cognitive decline.^[5]
• Psychosis develops in 30-50% of patients with Alzheimer disease over the course of illness, and is intrinsic to dementia with Lewy bodies.^[5-6]
• Apathy is the most common neuropsychiatric symptom across etiologies.^[5]
• Mortality is increased; median survival after diagnosis of Alzheimer disease is approximately 4-8 years, shorter for older-onset and for non-Alzheimer etiologies such as dementia with Lewy bodies.^[2,6]

The dementia syndrome is a final common pathway for a heterogeneous set of neurodegenerative, vascular, infectious, traumatic, and toxic insults. Etiologic subtypes have distinct molecular signatures, anatomic predilections, and clinical fingerprints, even when their late-stage presentations converge.

Alzheimer disease

• Pathologic hallmarks are extracellular amyloid-β plaques and intracellular neurofibrillary tangles of hyperphosphorylated tau, accompanied by synaptic loss and neuronal death.^[2,7]
• The amyloid cascade hypothesis posits that aggregation of amyloid-β42 is the upstream trigger; tau pathology and neuronal injury correlate more closely with cognitive symptoms than amyloid burden.^[7]
• Neurodegeneration begins in entorhinal cortex and hippocampus and spreads to temporoparietal association cortex, sparing primary motor and sensory areas until late.^[2]
• The cholinergic deficit from nucleus basalis of Meynert degeneration underlies the rationale for cholinesterase inhibitor therapy.^[2]
• Genetics: autosomal dominant early-onset forms involve APP, PSEN1, and PSEN2; late-onset Alzheimer disease is strongly influenced by APOE ε4 (one allele triples risk, two alleles raise it roughly 12-fold).^[2,7]

Vascular neurocognitive disorder

• Caused by ischemic, hemorrhagic, or hypoperfusion injury — large-vessel strokes, lacunar infarcts, microinfarcts, white matter disease, and amyloid angiopathy all contribute.^[8]
• Cognitive profile is typically dysexecutive with relative sparing of episodic memory early on.^[8]
• Stepwise decline and a temporal link to cerebrovascular events support the diagnosis; mixed pathology is the rule rather than the exception.^[8]

Dementia with Lewy bodies and Parkinson disease dementia:

• α-synuclein aggregation in cortical and brainstem Lewy bodies drives both entities; they are distinguished by the temporal relationship between cognitive and motor symptoms (the so-called one-year rule).^[6]
• Cholinergic deficits are even more pronounced than in Alzheimer disease, contributing to the often-robust response to cholinesterase inhibitors.^[6]
• Severe neuroleptic sensitivity, including precipitation of parkinsonism, autonomic instability, and acute confusion, follows from nigrostriatal vulnerability.^[6]

Frontotemporal lobar degeneration

• A heterogeneous group with frontal and anterior temporal atrophy, characterized at the molecular level by tau, TDP-43, or FUS inclusions.^[3]
• Behavioral variant frontotemporal dementia presents with disinhibition, apathy, loss of empathy, perseveration, and dietary changes; primary progressive aphasia variants present with language decline.^[3]
• Strong genetic component: MAPT, GRN, and C9orf72 expansions account for a substantial fraction of familial cases.^[3]

Other etiologies

• Traumatic brain injury, chronic traumatic encephalopathy, HIV-associated neurocognitive disorder, prion diseases (notably Creutzfeldt-Jakob disease), normal pressure hydrocephalus, and chronic alcohol use (including WKS) each have distinct trajectories and management implications.^[2]
• Reversible or partially reversible contributors — vitamin B12 deficiency, hypothyroidism, neurosyphilis, and medication effects — must be excluded before settling on a neurodegenerative diagnosis.^[2,9]

DSM-5-TR defines major neurocognitive disorder as significant cognitive decline in one or more cognitive domains that interferes with independence in everyday activities. The decline must not occur exclusively during delirium and must not be better explained by another mental disorder.^[10]

Core criteria

• Evidence of significant cognitive decline from a prior level of performance in one or more cognitive domains: complex attention, executive function, learning and memory, language, perceptual-motor, or social cognition.^[10]
• The decline is documented by both concern from the patient, informant, or clinician AND substantial impairment on objective testing (typically ≥2 standard deviations below appropriate norms, or approximately the third percentile).^[10]
• The cognitive deficits interfere with independence in everyday activities — at minimum, requiring assistance with complex instrumental activities of daily living such as managing finances or medications.^[10]
• The deficits do not occur exclusively in the context of delirium and are not better explained by another mental disorder.^[10]

Severity specifiers

• Mild: difficulties with instrumental activities of daily living (housework, managing money).^[10]
• Moderate: difficulties with basic activities of daily living (feeding, dressing).^[10]
• Severe: fully dependent.^[10]

Etiologic subtype specifiers

• Specify the suspected etiologic subtype (Alzheimer disease, vascular, Lewy bodies, frontotemporal, traumatic brain injury, Parkinson disease, HIV infection, prion disease, Huntington disease, another medical condition, substance/medication-induced, multiple etiologies, or unspecified).^[10]
• Each subtype is further qualified as probable (genetic evidence or characteristic clinical pattern with progressive decline) or possible (typical pattern without confirmatory evidence).^[10]

With or without behavioral disturbance

• Specify with behavioral disturbance when clinically significant agitation, psychotic features, depression, anxiety, apathy, or other behavioral symptoms accompany the cognitive decline.^[10]

Relationship to mild neurocognitive disorder

• Mild neurocognitive disorder applies when objective testing shows decline (typically 1-2 standard deviations below norms) but the patient retains independence with extra effort or compensation.^[10]
• Progression from mild to major neurocognitive disorder occurs at roughly 10-15% per year in clinic-based samples of amnestic mild cognitive impairment.^[2,11]

ICD-11 differences

• ICD-11 retains the term "dementia" within the chapter on neurocognitive disorders and aligns broadly with DSM-5-TR on syndrome definition and etiologic subtyping, though the threshold language and operationalization differ somewhat.^[12]

Although every etiologic subtype carries its own fingerprint, the dementia syndromes share a recognizable arc: insidious onset, progressive decline, accumulating functional impairment, and a constellation of behavioral and psychological symptoms that often eclipse the cognitive deficits in clinical importance.

Cognitive features by domain

• Memory: Episodic memory loss with early hippocampal involvement is the hallmark of typical Alzheimer disease; word-list learning, delayed recall, and recognition memory are characteristically impaired.^[2]
• Executive function: Impaired planning, set-shifting, and working memory predominate in vascular and frontotemporal etiologies.^[3,8]
• Language: Anomia is common across etiologies; primary progressive aphasia variants present with isolated language decline.^[3]
• Visuospatial: Posterior cortical atrophy presents with progressive visuospatial dysfunction (Balint syndrome features, simultanagnosia) as the leading symptom.^[2]
• Social cognition: Loss of empathy, disinhibition, and impaired theory of mind are early features of behavioral variant frontotemporal dementia.^[3]

Behavioral and psychological symptoms of dementia

• Apathy is the most prevalent neuropsychiatric symptom, appearing in over half of patients with Alzheimer disease.^[5]
• Depression occurs in approximately 20-30% and may be difficult to distinguish from apathy.^[5]
• Agitation and aggression escalate with disease severity and are leading drivers of nursing home placement.^[5]
• Psychosis — visual hallucinations are characteristic of dementia with Lewy bodies; delusions of theft, infidelity, or misidentification (Capgras) are common in moderate Alzheimer disease.^[5-6]
• Sleep disturbance includes sundowning, fragmented sleep, and — diagnostically important — REM sleep behavior disorder, which precedes synucleinopathies by years to decades.^[6]

Course and trajectory

• Typical Alzheimer disease progresses gradually over 8-10 years from preclinical to severe stages.^[2]
• Vascular neurocognitive disorder classically progresses stepwise, though confluent small-vessel disease can produce a gradual course indistinguishable from Alzheimer disease.^[8]
• Dementia with Lewy bodies typically has a more rapid course and earlier loss of independence than Alzheimer disease.^[6]
• Rapidly progressive dementia (months rather than years) should prompt evaluation for prion disease, autoimmune encephalitis, paraneoplastic syndromes, and treatable mimics.^[2]

Red flags suggesting non-Alzheimer or non-degenerative cause:

• Young age of onset (<65), rapid progression, early prominent gait disorder, early prominent behavioral change, early hallucinations or parkinsonism, focal neurologic signs, seizures, or systemic features.^[2,9]

The cardinal task is to separate major neurocognitive disorder from its three most common imitators — delirium, depression, and normal aging — and then to distinguish among etiologic subtypes. A careful informant history and bedside cognitive examination resolve most of the differential.

Distinguishing the major syndromes

Distinguishing among etiologic subtypes

Medical and substance mimics to exclude

• Vitamin B12 deficiency, folate deficiency, hypothyroidism, hyperthyroidism, hypercalcemia, hyponatremia, hepatic encephalopathy, uremia.^[9]
• Neurosyphilis, HIV, Lyme disease (in endemic areas), Whipple disease, autoimmune and limbic encephalitis.^[9]
• Normal pressure hydrocephalus (the classic triad of gait apraxia, urinary incontinence, and cognitive impairment).^[2]
• Chronic subdural hematoma, primary or metastatic brain tumor, obstructive sleep apnea.^[9]
• Medication effects: anticholinergics, benzodiazepines, opioids, sedating antihistamines, anticonvulsants, and polypharmacy in general.^[15]
• Substance use: chronic heavy alcohol use, sedative-hypnotic withdrawal, inhalants.^[2]

The diagnostic workup combines a structured history, a focused cognitive examination, a physical and neurologic exam, basic laboratory screening, and structural neuroimaging. The depth of biomarker testing depends on diagnostic uncertainty, age of onset, and availability.

History — gather from the patient and an informant separately:

• Timeline and trajectory: when did the patient last seem fully themselves, and what was the first noticeable change.^[9]
• Functional impact: which instrumental activities of daily living are now requiring help (finances, medications, transportation, complex meal preparation).^[9]
• Domain-specific symptoms: memory, language, visuospatial, executive, behavioral.^[9]
• Neurologic and motor history: falls, gait change, tremor, focal weakness, seizures, stroke.^[9]
• Sleep history including REM sleep behavior disorder (acting out dreams).^[6]
• Psychiatric history: depression, anxiety, psychosis, prior cognitive episodes.^[5]
• Medical history: cardiovascular risk, head trauma, alcohol and substance use, HIV risk, occupational toxin exposure.^[9]
• Medication review with attention to anticholinergic burden and sedatives.^[15]
• Family history of dementia (particularly young-onset).^[3]

Examination

• General medical examination including cardiovascular assessment, hearing, and vision.^[9]
• Neurologic examination targeting gait, tone (lead-pipe rigidity, cogwheeling), tremor, asymmetric findings, frontal release signs, and ocular motility (downgaze palsy in progressive supranuclear palsy).^[9]
• Functional assessment with a validated instrument such as the Functional Activities Questionnaire.^[9]

Validated cognitive screening and rating scales

• Mini-Mental State Examination (MMSE) — score out of 30; <24 traditionally flagged but insensitive to mild deficits and to executive dysfunction.^[16]
• Montreal Cognitive Assessment (MoCA) — score out of 30; cutoff approximately <26; more sensitive than MMSE for mild neurocognitive disorder and for vascular and frontotemporal patterns.^[17]
• Mini-Cog — 3-item recall plus clock draw; rapid primary care screen.^[9]
• Saint Louis University Mental Status Examination — sensitive to mild impairment.^[9]
• Neuropsychological battery — indicated when screening is equivocal, when atypical patterns are suspected, or to establish a detailed baseline.^[9]
• Neuropsychiatric Inventory — characterizes and quantifies behavioral and psychological symptoms; widely used in clinical trials.^[5]
• Cornell Scale for Depression in Dementia — depression assessment that does not rely on self-report.^[5]

Laboratory studies — exclude reversible contributors

• Complete blood count, comprehensive metabolic panel, thyroid-stimulating hormone, vitamin B12, and folate are standard.^[9]
• HIV, rapid plasma reagin or treponemal-specific testing, and Lyme serology are guided by epidemiology and clinical features.^[9]
• Toxicology, ceruloplasmin (in young-onset cases), and heavy metals when clinically indicated.^[9]

Neuroimaging

• Structural imaging — MRI is preferred over CT — should be obtained at least once during workup to identify strokes, white matter disease, hydrocephalus, mass lesions, and patterns of atrophy.^[9]
• 18F-FDG-PET shows hypometabolism patterns useful when clinical diagnosis is uncertain (temporoparietal in Alzheimer disease, frontotemporal in FTD).^[2,18]
• Amyloid PET and tau PET confirm Alzheimer pathology and are increasingly used in clinical trials and in selected cases.^[7,18]
• DaTscan (dopamine transporter imaging) helps confirm dementia with Lewy bodies by demonstrating nigrostriatal denervation.^[6]

Cerebrospinal fluid and emerging biomarkers

• CSF amyloid-β42 (decreased), total tau (increased), and phosphorylated tau (increased) support Alzheimer pathology.^[7]
• Plasma p-tau217 and other blood-based biomarkers show high concordance with amyloid PET in research and emerging clinical use.^[7,18]
• Genetic testing is appropriate in young-onset cases, strong family histories suggesting autosomal dominant inheritance, or specific phenotypes (such as FTD-ALS spectrum, where C9orf72 testing is high-yield).^[3]

What NOT to order routinely

• Routine EEG is not indicated unless seizures or rapidly progressive dementia (where periodic complexes may suggest Creutzfeldt-Jakob disease) are suspected.^[9]
• APOE genotyping is not recommended for routine clinical diagnosis; the result is probabilistic, not diagnostic, and creates counseling complexities.^[2,9]

Management of major neurocognitive disorder is multimodal and stage-dependent. Disease-modifying options are limited, recent, and confined largely to early Alzheimer disease; the bulk of clinical work is symptomatic, behavioral, and supportive.^[19]

Treatment goals

• Slow cognitive decline where evidence supports it, particularly in early Alzheimer disease.^[19]
• Manage behavioral and psychological symptoms of dementia (BPSD) — agitation, psychosis, depression, sleep disturbance — with non-pharmacologic strategies first.^[20]
• Preserve function and safety: driving, finances, medication management, falls prevention.^[20]
• Address caregiver burden, which independently predicts patient outcomes and institutionalization.^[21]

Pharmacotherapy

• Cholinesterase inhibitors (donepezil, rivastigmine, galantamine) are first-line for mild-to-moderate Alzheimer disease and for dementia with Lewy bodies, where response is often more robust than in Alzheimer disease.^[19,22]
  • donepezil 5-10 mg PO QHS titrated after 4-6 weeks; 23 mg dose is approved for moderate-to-severe disease but offers marginal benefit at higher GI cost.^[19]
  • rivastigmine 1.5-6 mg PO BID or transdermal patch (4.6, 9.5, 13.3 mg/24h); patch reduces GI adverse effects.^[19]
  • galantamine 4-12 mg PO BID immediate-release or once-daily extended-release.^[19]
  • Effect size is modest: roughly 2-3 point improvement on the ADAS-Cog over 6 months, without halting underlying decline.^[22]
• Memantine, an NMDA receptor antagonist, is approved for moderate-to-severe Alzheimer disease and may be combined with a cholinesterase inhibitor.^[19]
  • memantine 5-10 mg PO BID (or 28 mg extended-release daily) after titration.^[19]
• Anti-amyloid monoclonal antibodies (lecanemab, donanemab) are the first agents with evidence of disease modification in early Alzheimer disease, removing amyloid plaque on PET and modestly slowing clinical decline over 18 months.^[23-24]
  • Eligibility requires biomarker-confirmed amyloid pathology and early-stage disease (mild cognitive impairment or mild dementia).^[23]
  • Amyloid-related imaging abnormalities (ARIA-E edema, ARIA-H hemorrhage) are the signature risk, particularly in APOE ε4 homozygotes.^[23-24]
  • MRI surveillance before infusions 5, 7, and 14 is standard for lecanemab.^[23]

• Vascular cognitive impairment is managed primarily through aggressive vascular risk-factor control (hypertension, diabetes, hyperlipidemia, smoking, atrial fibrillation); cholinesterase inhibitors offer small benefits and are not formally approved.^[25]
• Frontotemporal dementia has no approved disease-modifying or symptomatic cognitive treatment; cholinesterase inhibitors may worsen behavioral symptoms and should generally be avoided. SSRIs may help disinhibition and compulsive behaviors.^[26]
• Behavioral and psychological symptoms:
  • Non-pharmacologic strategies are first-line: identifying and addressing unmet needs (pain, hunger, constipation, infection), structured activity, music therapy, caregiver education.^[20,27]
  • Depression: SSRIs (sertraline, citalopram) are preferred; evidence is mixed and effect sizes modest in dementia-associated depression.^[28]
  • Agitation and psychosis: brexpiprazole is FDA-approved for agitation associated with Alzheimer disease and modestly reduces symptoms; risperidone, olanzapine, and aripiprazole have evidence but carry an FDA boxed warning for increased mortality in elderly patients with dementia-related psychosis.^[29-30]
  • brexpiprazole 0.5-3 mg PO QD titrated over weeks for Alzheimer-associated agitation.^[29]
  • Avoid benzodiazepines for chronic management; they worsen cognition, increase falls, and risk paradoxical disinhibition.^[20]
  • Avoid first-generation antipsychotics in Lewy body dementia and Parkinson disease dementia, where severe neuroleptic sensitivity reactions can occur; if antipsychotic is necessary, low-dose quetiapine or pimavanserin are preferred.^[31]

• Sleep disturbance:
  • Sleep hygiene, light exposure, and treatment of underlying contributors (pain, nocturia, sleep apnea) come first.^[20]
  • Melatonin and trazodone have modest evidence; suvorexant is FDA-approved for insomnia in Alzheimer disease.^[32]
  • Avoid Z-drugs (zolpidem, eszopiclone) and diphenhydramine; both worsen cognition and falls.^[20]
• REM sleep behavior disorder in Lewy body dementia responds to bedtime melatonin or low-dose clonazepam with caution given falls risk.^[33]

Psychotherapy

• Cognitive stimulation therapy (group-based, structured activities) shows small but consistent cognitive and quality-of-life benefits in mild-to-moderate dementia and is recommended by NICE.^[34]
• Reminiscence therapy, validation therapy, and reality orientation have weaker but supportive evidence for mood and engagement.^[34]
• Cognitive rehabilitation (individualized goal-oriented strategies) shows benefit for everyday functioning in mild dementia and MCI.^[35]
• Caregiver-directed interventions (psychoeducation, skills training, the REACH and STrAtegies for RelaTives programs) reduce caregiver depression and delay institutionalization.^[21,36]
• Cognitive behavioral therapy adapted for dementia can address comorbid anxiety and depression in mild stages.^[36]

Neuromodulation

• Repetitive transcranial magnetic stimulation (rTMS) has emerging evidence for cognitive enhancement in mild-to-moderate Alzheimer disease, with effect sizes that remain small and heterogeneous; not standard of care.^[37]
• Electroconvulsive therapy is reserved for severe comorbid depression or treatment-resistant agitation when other measures fail; cognitive risks are higher in this population, and right unilateral ultrabrief-pulse technique is preferred.^[38]
• Deep brain stimulation of the fornix is investigational for Alzheimer disease with mixed results in randomized trials.^[37]

Adjunctive

• Address vascular risk factors aggressively: blood pressure control in midlife reduces dementia incidence (SPRINT MIND).^[39]
• Hearing aids and cataract surgery: correcting sensory loss reduces cognitive decline and behavioral symptoms; the ACHIEVE trial showed hearing intervention slowed cognitive decline in at-risk older adults.^[40]
• Physical activity, particularly aerobic exercise, is recommended for cognitive and functional benefits in MCI and mild dementia.^[34]
• Mediterranean and MIND diets are associated with lower dementia incidence in observational studies; randomized evidence is limited.^[41]
• Deprescribing: review for anticholinergic burden (oxybutynin, diphenhydramine, tricyclics), benzodiazepines, and Z-drugs, each of which contributes to cognitive worsening and falls.^[20,42]
• Advance care planning is essential early, while the patient retains capacity, covering medical decision-making, finances, and goals of care.^[43]

The evidence base for symptomatic pharmacotherapy in Alzheimer disease is mature but modest; anti-amyloid antibodies represent the first credible disease-modifying class but bring real safety trade-offs. Non-pharmacologic approaches and caregiver support have a stronger evidence base than is often appreciated.

Symptomatic and disease-modifying treatments for major neurocognitive disorder carry meaningful risks, particularly in a frail elderly population, and the evidence base has well-recognized weaknesses.

Common adverse effects

• Cholinesterase inhibitors cause GI upset (nausea, vomiting, diarrhea, anorexia), weight loss, vivid dreams, urinary frequency, and bradycardia or syncope through vagotonic effects.^[19]
• Memantine is generally well tolerated; dizziness, headache, and confusion are most common.^[19]
• Antipsychotics in elderly patients cause sedation, falls, extrapyramidal symptoms, metabolic disturbance, anticholinergic effects, and orthostasis disproportionately to younger adults.^[30]

Serious or rare adverse effects

• Antipsychotics carry an FDA boxed warning for increased all-cause mortality in elderly patients with dementia-related psychosis (approximately 1.6-1.7x baseline).^[30]
• Anti-amyloid monoclonal antibodies cause ARIA-E (edema) in roughly 12-25% and ARIA-H (microhemorrhage) in 14-30% of treated patients; symptomatic cases occur in a minority but include rare fatal cerebral hemorrhage.^[23-24]
• APOE ε4 homozygotes carry the highest ARIA risk and warrant careful counseling before treatment.^[23]
• Cholinesterase inhibitors can precipitate syncope, falls, and pacemaker placement in vulnerable patients.^[44]
• Severe neuroleptic sensitivity reactions in Lewy body dementia can cause irreversible parkinsonism, autonomic instability, and death.^[31]

Monitoring and discontinuation

• Cholinesterase inhibitors require periodic review of benefit; many guidelines recommend a trial of discontinuation if cognitive decline is rapid despite treatment.^[19]
• Antipsychotics for BPSD should be reviewed for deprescribing every 3-6 months; abrupt discontinuation rarely causes withdrawal in this population.^[30]
• Lecanemab and donanemab require MRI before infusions 5, 7, and 14, and immediately for any new neurologic symptoms.^[23]
• Anticholinergic burden should be reviewed at every visit; cumulative anticholinergic exposure is independently associated with dementia risk.^[42]

Limitations of the evidence base

• Most pharmacologic trials in dementia were short (6-12 months) and may overstate or understate long-term effects.^[22]
• Trial populations were predominantly white, well-educated, and free of significant medical comorbidity, limiting generalizability.^[23-24]
• Outcomes have relied on cognitive scales (ADAS-Cog, CDR-SB) whose clinical meaningfulness at small effect sizes is debated.^[45]
• Non-pharmacologic interventions are difficult to blind and many trials are at moderate-to-high risk of bias.^[34]
• Long-term safety data for anti-amyloid antibodies extend only to the trial periods; population-level effects are emerging.^[23-24]

Cognitive decline does not present uniformly across the lifespan, and several subpopulations require modified diagnostic and management approaches.

Young-onset dementia

• Onset before age 65 affects an estimated 38-260 per 100,000 adults and is more likely to be frontotemporal, genetic (autosomal dominant Alzheimer disease, MAPT, GRN, C9orf72), or secondary to traumatic, infectious, or metabolic causes.^[46]
• Genetic counseling and consideration of testing are appropriate when family history suggests autosomal dominant inheritance.^[46]
• Functional impact is disproportionate: patients are often still working, with dependent children, and economic consequences are severe.^[46]

Down syndrome

• Adults with Down syndrome have a lifetime Alzheimer disease risk approaching 90% by age 65 due to APP gene triplication on chromosome 21.^[47]
• Clinical recognition is complicated by baseline intellectual disability; serial functional assessment is the cornerstone of detection.^[47]

Late-life onset (≥80 years)

• Mixed pathology is the rule rather than the exception; Alzheimer, vascular, and TDP-43 (limbic-predominant age-related TDP-43 encephalopathy, LATE) co-occur frequently.^[48]
• The benefits of disease-modifying therapy are less established in this group, and ARIA risk with anti-amyloid antibodies is higher.^[23-24]

Comorbid medical illness

• Cognitive impairment in heart failure, COPD, end-stage renal disease, and chronic liver disease may improve with optimization of the underlying condition.^[49]
• Polypharmacy review and anticholinergic deprescribing are higher-yield than additional cognitive enhancers in many medically complex patients.^[42]

Comorbid substance use

• Alcohol-related cognitive impairment may partially reverse with sustained abstinence, thiamine repletion, and nutritional rehabilitation; assessment is best deferred 6-12 weeks after abstinence is achieved.^[50]
• Chronic cannabis, benzodiazepine, and opioid exposure should be tapered when feasible before finalizing diagnosis.^[50]

Cultural and linguistic considerations

• Cognitive testing instruments developed in English-speaking, educated populations underperform in patients with low formal education, non-native language exposure, or different cultural frames.^[51]
• Use validated translations, culturally-adapted instruments (RUDAS, MoCA-B), and longitudinal functional assessment from a knowledgeable informant.^[51]

The natural history of major neurocognitive disorder varies by etiology, comorbidity, and stage at diagnosis, but the trajectory is progressive in nearly all cases. Median survival from diagnosis of Alzheimer disease ranges from 4 to 8 years, shorter with later-stage diagnosis, male sex, and significant comorbidity.^[52]

Trajectory by etiology

• Alzheimer disease typically declines gradually over 8-10 years from prodromal symptoms to death, though heterogeneity is substantial.^[52]
• Vascular dementia often shows stepwise decline aligned with cerebrovascular events but may also be gradual when small-vessel disease predominates.^[25]
• Dementia with Lewy bodies progresses faster than Alzheimer disease in most cohorts, with median survival of 5-7 years from diagnosis.^[31]
• Frontotemporal dementia has variable course depending on subtype; behavioral-variant FTD median survival is roughly 6-11 years from symptom onset.^[26]
• Creutzfeldt-Jakob disease and other prion dementias progress to death within months in most cases.^[15]

Functional milestones

• Loss of complex IADLs (finances, medications, driving) typically precedes loss of basic ADLs by years.^[52]
• Loss of independent ambulation, continence, and oral intake mark advanced disease and are associated with median survival of 6-12 months.^[52]
• Hospice eligibility for advanced dementia is typically met with FAST stage 7 and recent complications such as aspiration pneumonia, pressure ulcer, or weight loss.^[53]

Mortality

• Aspiration pneumonia is the most common immediate cause of death in advanced dementia.^[52]
• Mortality is also driven by falls, urinary tract infection, dehydration, and reduced oral intake.^[52]
• Suicide risk is elevated in early-stage dementia, particularly around the time of diagnosis disclosure, and warrants explicit assessment.^[54]

Acute presentations in patients with established or suspected dementia require careful triage. Delirium is the most common cause of an abrupt change in cognition or behavior in this population and must be excluded before attributing decline to disease progression.^[8]

Indications for acute evaluation or hospitalization

• Sudden change in cognition, behavior, or level of consciousness: workup for delirium with focused medical evaluation.^[8]
• New focal neurologic signs: urgent neuroimaging to exclude stroke, hemorrhage, subdural hematoma, or mass lesion.^[55]
• Severe agitation, aggression, or psychosis with risk to self or others when outpatient measures have failed.^[20]
• Suicidal ideation or behavior, particularly in early-stage disease with retained insight.^[54]
• Significant medication adverse effects (ARIA symptoms, serotonin syndrome, falls with injury).^[23-24]
• Failure to thrive, severe self-neglect, or breakdown of caregiving arrangements.^[20]

Agitation management

• Identify and treat reversible contributors first: pain, infection, constipation, urinary retention, dehydration, environmental stressors.^[20]
• De-escalation, redirection, and a calm low-stimulus environment are first-line.^[20]
• Pharmacologic management for dangerous agitation: low-dose haloperidol or olanzapine for emergencies; avoid benzodiazepines except in alcohol withdrawal or Lewy body dementia, where they are contraindicated.^[20,31]
• haloperidol 0.25-0.5 mg PO or IM is often used acutely; doses substantially higher than this in elderly patients increase QTc, EPS, and mortality risk.^[20]

Driving and capacity

• Driving safety should be assessed at diagnosis and at each follow-up; formal road testing or occupational therapy driving evaluation may be required.^[56]
• Capacity assessments (medical decision-making, financial, testamentary) are decision-specific; a global "incompetent" label is incorrect and clinically unhelpful.^[57]
• Mandatory reporting requirements for impaired driving vary by jurisdiction; familiarity with local law is essential.^[56]

Elder abuse and self-neglect

• Cognitive impairment increases vulnerability to financial exploitation, neglect, and physical abuse; screen at every visit and report per local statutes.^[58]

Several active debates shape how the field talks about diagnosis, biomarkers, and disease-modifying therapy.

Biomarker-based vs syndromic diagnosis

• The 2024 NIA-AA revised criteria propose defining Alzheimer disease biologically (amyloid + tau biomarkers) regardless of clinical symptoms, a shift from the 2011 clinical-pathological framework that would diagnose many cognitively normal older adults with the disease.^[14-16]
• Critics argue that asymptomatic biomarker positivity is a risk state, not a disease, and that conflation will medicalize aging and inflate prevalence.^[59]
• DSM-5-TR retains the syndromic definition: cognitive decline with functional impairment is still required to diagnose major neurocognitive disorder.^[10]

Anti-amyloid monoclonal antibodies

• Lecanemab and donanemab slowed clinical decline by roughly 25-35% over 18 months in early Alzheimer disease populations, but the absolute differences on the Clinical Dementia Rating Sum of Boxes were small and of debated clinical meaningfulness.^[23-24]
• Amyloid-related imaging abnormalities (ARIA-E edema, ARIA-H microhemorrhage) occur in 12-35% of treated patients, with higher rates in APOE ε4 homozygotes.^[23-24]
• Cost, monitoring burden (serial MRIs, infusion infrastructure), and exclusion of patients on anticoagulation limit real-world uptake; several European regulators initially declined approval citing unfavorable benefit-risk.^[60]

Antipsychotics for BPSD

• The black-box warning on mortality in dementia-related psychosis applies to all antipsychotics, yet behavioral emergencies routinely require them; the field has not converged on how to weigh acute benefit against accumulated mortality risk.^[30]
• Brexpiprazole's 2023 FDA approval for agitation in Alzheimer dementia is the first indication-specific approval but rests on modest effect sizes and the same mortality signal.^[29]

Cannabinoids, psychedelics, and emerging therapies

• Nabilone and dronabinol have small trials in agitation with mixed results; cannabidiol lacks high-quality RCT evidence in dementia despite widespread caregiver interest.^[61]
• Psilocybin and ketamine are under investigation for depression in early dementia but remain experimental.^[62]

Driving and capacity

• No single cognitive score reliably predicts driving safety; on-road testing remains the reference standard, and clinicians vary widely in when to recommend cessation.^[63]
• Capacity is decision-specific; a patient may retain capacity for some decisions (where to live) while lacking it for others (complex financial transactions).^[64]

• Major neurocognitive disorder requires cognitive decline plus loss of independence in instrumental activities of daily living; mild neurocognitive disorder spares independence.^[10]
• Alzheimer disease accounts for 60-80% of dementia cases and characteristically presents with insidious episodic memory loss followed by visuospatial and language decline.^[1-2]
• Vascular neurocognitive disorder classically presents with stepwise decline, executive dysfunction, and focal neurologic signs; gait disturbance and incontinence often precede memory loss.^[8,25]
• The clinical triad of dementia with Lewy bodies is fluctuating cognition, recurrent well-formed visual hallucinations, and spontaneous parkinsonism; REM sleep behavior disorder may precede dementia by years.^[6,33]
• Patients with dementia with Lewy bodies have severe antipsychotic sensitivity reactions; first-generation agents are contraindicated and second-generation agents must be used cautiously.^[6,31]
• Behavioral-variant frontotemporal dementia presents with disinhibition, apathy, loss of empathy, and hyperorality, typically in the 50s-60s with preserved early memory.^[3]
• Normal pressure hydrocephalus presents with the wet-wobbly-wacky triad (urinary incontinence, magnetic gait, cognitive slowing) and may improve with ventriculoperitoneal shunting.^[27]
• APOE ε4 is the strongest common genetic risk factor for late-onset Alzheimer disease; one allele approximately triples risk and two alleles increase risk roughly twelvefold.^[12]
• The MoCA is more sensitive than the MMSE for mild cognitive impairment; both are screening tools, not diagnostic of dementia.^[16-17]
• Cholinesterase inhibitors (donepezil, rivastigmine, galantamine) produce modest symptomatic benefit in Alzheimer disease; bradycardia and syncope are key adverse effects.^[19,22,44]
• Memantine, an NMDA receptor antagonist, is indicated for moderate-to-severe Alzheimer disease and is well tolerated.^[19]
• Antipsychotics carry an FDA black-box warning for increased mortality (roughly 1.6-1.7-fold) when used for dementia-related psychosis.^[30]
• Delirium classically features acute onset, fluctuating course, and inattention; dementia features insidious onset and preserved attention until late stages.^[13]
• Pseudodementia of depression improves with antidepressant treatment and shows effort-dependent rather than amnestic cognitive deficits.^[5,28]
• Reversible contributors to cognitive decline include B12 deficiency, hypothyroidism, neurosyphilis, normal pressure hydrocephalus, and chronic subdural hematoma.^[9,27]

No external funding. No conflicts of interest declared. Peer-review status: pending.